- Home
- FHN vs EXEL Comparison
FHN vs EXEL Comparison
Compare FHN & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FHN | EXEL |
|---|---|---|
| Founded | 1864 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0B | 11.1B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | FHN | EXEL |
|---|---|---|
| Price | $22.86 | $44.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 24 |
| Target Price | $24.05 | ★ $44.73 |
| AVG Volume (30 Days) | ★ 5.7M | 2.5M |
| Earning Date | 01-15-2026 | 11-04-2025 |
| Dividend Yield | ★ 2.64% | N/A |
| EPS Growth | 20.88 | ★ 53.55 |
| EPS | 1.65 | ★ 2.38 |
| Revenue | ★ $3,184,000,000.00 | $2,288,218,000.00 |
| Revenue This Year | $12.70 | $9.14 |
| Revenue Next Year | $2.54 | $12.51 |
| P/E Ratio | ★ $13.75 | $18.67 |
| Revenue Growth | 3.68 | ★ 9.93 |
| 52 Week Low | $15.19 | $31.90 |
| 52 Week High | $23.70 | $49.62 |
Technical Indicators
Market Signals| Indicator | FHN | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 62.34 | 63.52 |
| Support Level | $22.26 | $43.00 |
| Resistance Level | $22.98 | $44.79 |
| Average True Range (ATR) | 0.50 | 1.03 |
| MACD | 0.15 | 0.06 |
| Stochastic Oscillator | 91.86 | 83.48 |
Price Performance
Historical ComparisonAbout FHN First Horizon Corporation
First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The company's reportable segments are: Commercial, Consumer & Wealth, Wholesale, and Corporate. The majority of its revenue is generated from Commercial, Consumer & Wealth. The Commercial, Consumer & Wealth segment offers financial products and services, including traditional lending and deposit taking, to commercial and consumer clients in the southern USA and other selected markets.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.